The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review

MLA

Hailey Saunders, et al. “The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.” Value in Health, vol. 25, July 2022, pp. 1235–52. EBSCOhost, https://doi.org/10.1016/j.jval.2021.12.016.

APA

Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco, & Wanrudee Isaranuwatchai. (2022). The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health, 25, 1235–1252. https://doi.org/10.1016/j.jval.2021.12.016

Chicago

Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, et al. 2022. “The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.” Value in Health 25 (July): 1235–52. doi:10.1016/j.jval.2021.12.016.